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The aim of this study is to evaluate the retention rates and reasons for discontinuation for
seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting
of elderly patients (65 years of age or older) with rheumatoid arthritis (RA).
Methods
This multi-center, retrospective study assessed 1,098 treatment courses of 661 patients
with bDMARDs from 2009 to 2018 (females, 80.7%; baseline age, 71.7 years; disease dura-
tion 10.5 years; rheumatoid factor positivity 81.3%; Disease Activity Score in 28 joints using
erythrocyte sedimentation rate, 4.6; concomitant prednisolone dose 2.8 mg/day (45.6%)
and methotrexate dose 4.4 mg/week (56.4%); and 60.2% patients were bio-naïve). Treat-
ment courses included abatacept (ABT; n = 272), tocilizumab (TCZ; n = 234), etanercept
(ETN; n = 184), golimumab (GLM; n = 159), infliximab (IFX; n = 101), adalimumab (ADA; n =
97), and certolizumab pegol (CZP; n = 51). Drug retention rates and discontinuation reasons
were estimated at 36 months using the Kaplan-Meier method and adjusted for potential clini-
cal confounders (age, sex, disease duration, concomitant PSL and MTX, starting date and
switched number of bDMARDs) by Cox proportional hazards modeling.
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Results
A total of 51.2% of treatment courses were stopped, with 25.1% stopping due to lack of
effectiveness, 11.8% due to toxic adverse events, 9.7% due to non-toxic reasons, and 4.6%
due to remission. Drug retention rates for each discontinuation reason were as follows; lack
of effectiveness [from 55.4% (ETN) to 81.6% (ABT); with significant differences between
groups (Cox P<0.001)], toxic adverse events [from 79.3% (IFX) to 95.4% (ABT), Cox P =
0.043], and remission [from 94.2% (TCZ) to 100.0% (CZP), Cox P = 0.58]. Finally, overall
retention rates excluding non-toxic reasons and remission for discontinuation ranged from
50.0% (ETN) to 78.1% (ABT) (Cox P<0.001).
Conclusions
ABT showed lowest discontinuation rate by lack of effectiveness and by toxic adverse
events, which lead to highest overall retention rates (excluding non-toxic reasons and remis-
sion) among seven bDMARDs in adjusted model of elderly RA patients.
Introduction
Tumor necrosis factor inhibitors (TNFi) were the first biological disease-modifying antirheu-
matic drugs (bDMARDs) used for rheumatoid arthritis (RA), and evidence has accumulated
regarding the safety, effectiveness, and tolerability of adalimumab (ADA), etanercept (ETN),
and infliximab (IFX) [1–5]. On the other hand, other TNFi such as golimumab (GLM) (2011)
and certolizumab pegol (CZP) (2013) recently received approval in Japan, and the European
League against Rheumatism (EULAR) announced a 2013 recommendation regarding the
management of RA with bDMARDs, in which CTLA4-Ig [abatacept (ABT)] and anti-interleu-
kin (IL)-6 receptor antibody [tocilizumab (TCZ)], are considered as equivalent as TNFi [6].
However, we still lack reliable evidence which directly compared the safety, effectiveness, and
tolerability of these seven bDMARDs.
In patients with RA, the population of older individuals [7], as well as its onset age is rapidly
increasing [8]. The treatment strategy of elderly patients is often influenced by its comorbidi-
ties (renal impairment, chronic lung disease, et al.) in a real-world setting, although the present
treatment recommendation is not distinguished by age or comorbidities [9]. On the other
hand, patients with elderly-onset RA is associated with higher inflammation and risk of rapid
joint destruction compared to younger-onset RA [10, 11], although elderly RA patients receive
less frequent of conventional synthetic DMARDs (csDMARDs) including methotrexate
(MTX) and bDMARDs treatment compared with younger RA patients [12].
Thus, investigating the effectiveness and safety of bDMARDs in elderly RA patients is of
great interests today. However, randomized controlled trials (RCTs) often recruits younger
age of patients with less comorbidities who are different from those in real-world settings [13].
Recently, cohort-based observational studies have increasingly been used to investigate the
performance of bDMARDs [1–4, 14–16], and drug retention is considered as an index of
safety, effectiveness, and tolerability [4, 17–19]. Treatment selection and discontinuation may
be influenced by factors such as differences among attending physicians and patient character-
istics, although the national health insurance in our country and multicenter studies may help
to decrease these possible bias (bDMARDs can be freely selected by attending physicians’
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discretion in our country) [17–19]. And as far as we know, there are no reports comparing the
effectiveness and safety of seven bDMARDs in elderly RA patients.
We have recently reported the drug retention and reasons for discontinuation among seven
biologics in all age of RA [20], and factors associated with the achievement of bDMARDs-free
remission [21] from our cohort. The aim of this multicenter, retrospective study was to clarify
the retention rates and reasons for discontinuation of seven bDMARDs in the real-world set-
ting of elderly (65 years of age or older) patients with RA.
Materials and methods
Patients
The Kansai Consortium for Well-being of Rheumatic Disease Patients (ANSWER) cohort is
an observational multicenter registry of patients with RA in the Kansai district of Japan. Data
from patients at seven institutes (Kyoto University, Osaka University, Osaka Medical College,
Kansai Medical University, Kobe University, Nara Medial University, and Osaka Red Cross
Hospital) were included. From 2009 to 2018, 4,461 patients with RA were registered, and
52,654 serial disease activities were available from the database. Data from patients with RA
introducing one of seven bDMARDs (ABT, ADA, CZP, ETN, GLM, IFX, and TCZ; including
both intravenous and subcutaneous agents, but excluding bio-similar agents) at 65 years of age
or older were retrospectively collected. In this study, patients who fulfilled the 1987 RA classifi-
cation criteria of the American College of Rheumatology [22], with data on starting and dis-
continuation dates for bDMARDs, and reasons for discontinuation, were included. In
addition, baseline demographic data such as age, sex, disease activity (Disease Activity Score in
28 joints using erythrocyte sedimentation rate [DAS28-ESR]), clinical disease activity index
(CDAI), duration of disease, number of previously administered bDMARDs, concomitant
doses of methotrexate (MTX) and prednisolone (PSL), rheumatoid factor (RF) and anti-cyclic
citrullinated peptide antibody (ACPA) positivity, and Health Assessment Questionnaire
[HAQ] disability index [DI] score were also collected [20].
Treatments were administered by the attending rheumatologists in accordance with guide-
lines of the Japan College of Rheumatology. The starting date of each biologic was classified into
three groups (2009–2012, 2013–2015, and 2016–2018). Drug retention was retrospectively eval-
uated as the duration until definitive treatment interruption. Reasons for discontinuation were
analyzed and classified into four major categories: 1) lack of effectiveness (including primary
and secondary); 2) disease remission; 3) toxic adverse events (infection, skin or systemic reac-
tion, and other toxic events, including hematologic, pulmonary, renal, cardiovascular complica-
tions, and malignancies, etc.); and 4) non-toxic reasons (patient preference, change in hospital,
desire for pregnancy, etc.). Physicians were allowed to cite only one reason for discontinuation
[20]. The representative facility of this registry is Kyoto University, and this observational study
was conducted in accordance with the Declaration of Helsinki, with approval by each ethics
committee of seven institutes (Kyoto University, Osaka University, Osaka Medical College,
Kansai Medical University, Kobe University, Nara Medial University, and Osaka Red Cross
Hospital). This study was approved by the Institutional Ethical Review Board of Osaka Univer-
sity Graduate School of Medicine (approval number: 15300), and the board waived the require-
ment for patients’ informed consent because of the anonymous nature of the data. Written
informed consent was obtained from participants in other institutes.
Statistical analysis
The survival curves of each biologic explained by specific causes were examined by the
Kaplan-Meier method and compared statistically using a stratified log-rank test. The time to
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discontinuation of biologics was analyzed using multivariate Cox proportional hazards model-
ing [1]. The proportion of treatment retention rates explained by specific causes was analyzed
at 36 months [20], and also adjusted by potential confounders that may influence drug discon-
tinuation and the incidence of adverse events, as previously described (age, sex, disease dura-
tion, concomitant PSL and MTX, starting date and switched number of bDMARDs) [1, 14–16,
23]. Statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical
University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical
Computing, Vienna, Austria) [24]. P<0.05 was considered statistically significant.
Results
Baseline characteristics
The study population was selected from all patients with RA in the ANSWER cohort
(n = 4461) who fulfilled the inclusion criteria (n = 661; 1098 bDMARDs treatment courses).
Baseline demographic and clinical characteristics of patients are shown in Table 1. Overall at
baseline, mean age was 71.7 years, 80.7% of participants were female, mean disease duration
was 10.5 years, RF positivity was 81.3%, ACPA positivity was 85.5%, mean DAS28-ESR score
was 4.6, CDAI was 17.3, and mean HAQ-DI score was 1.3. In addition, mean doses of con-
comitant medications were prednisolone (PSL) 2.8 mg/day (45.6%) and MTX 4.4 mg/week
(56.4%). The bDMARDs being administered for the first agent in 60.2% of treatment courses,
for the second agent in 22.1%, and for third or latter agent in 17.7%.















Age (years) 73.0±6.0 69.9±4.7 73.1±6.8 71.9±5.5 72.5±5.6 69.6±3.2 71.0±5.3
Female sex (%) 79.4 79.4 90.2 81.5 86.2 79.2 76.9
BMI (kg/m2) 21.7±3.5 21.9±3.5 22.4±3.6 22.2±3.5 22.8±3.5 22.6±3.4 22.0±3.3
Disease duration (years) 10.6±11.2 10.1±11.2 9.1±10.5 10.5±10.2 11.1±11.5 9.1±11.3 11.0±10.9
RF positivity (%) 83.4 79.0 89.4 85.2 73.7 75.3 82.8
ACPA positivity (%) 89.9 82.7 85.1 86.2 82.6 81.0 85.6
DAS28-ESR 4.5±1.2 4.5±1.2 5.1±1.5 4.7±1.3 4.4±1.3 5.0±1.5 4.8±1.3
CDAI 16.9±9.7 15.7±9.0 21.8±12.7 17.6±10.0 16.1±10.7 21.3±14.0 16.8±9.8
HAQ-DI 1.2±0.8 1.0±0.7 1.7±0.9 1.2±0.8 1.3±0.8 1.3±1.0 1.3±0.9
PSL usage (%) 46.8 41.1 37.3 47.8 41.4 48.4 47.8
PSL dose (mg/day) 3.1±7.3 2.9±4.9 1.7±2.6 2.8±3.6 2.3±3.6 3.1±5.9 2.8±3.9
MTX usage (%) 46.1 74.7 52.9 44.9 66.9 100.0 46.1
MTX dose (mg/week) 3.4±4.2 6.1±4.2 4.2±4.6 3.5±4.3 5.2±4.4 8.2±2.5 3.6±4.3
Starting date (2009–2012) (%) 16.1 54.6 0 56.5 17.0 67.3 30.8
Starting date (2013–2015) (%) 65.1 39.2 70.6 37.5 50.9 29.7 52.1
Starting date (2016–2018) (%) 18.8 6.2 29.4 6.0 32.1 3.0 17.1
1st bio (%) 66.5 59.8 58.8 71.2 45.3 86.1 43.6
2nd bio (%) 18.0 29.9 5.9 17.9 30.2 10.9 29.9
�3rd bio (%) 15.5 10.3 35.3 10.9 24.5 3.0 26.5
Values represent mean ± standard deviation (SD), unless otherwise noted. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept,
GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, BMI = body mass index, RF = rheumatoid factor, ACPA = anti-cyclic citrullinated peptide antibody,
DAS28-ESR = Disease Activity Score in 28 joints using erythrocyte sedimentation rate, CDAI = clinical disease activity index, HAQ-DI = Health Assessment
Questionnaire disability index, PSL = prednisolone, MTX = methotrexate, bio = biologic agent.
https://doi.org/10.1371/journal.pone.0216624.t001
Drug tolerability and discontinuation reasons of seven biologics in elderly patients with rheumatoid arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0216624 May 8, 2019 4 / 13
Drug retention
Overall, 562 treatment courses (51.2%) were stopped by 36 months. A total of 275 treatment
courses (25.1%) were stopped due to lack of effectiveness, 130 treatment courses (11.8%) due
to toxic adverse events, 106 treatment courses (9.7%) due to non-toxic reasons, and 51 treat-
ment courses (4.6%) due to remission.
Causes for discontinuation
Cause-specific cumulative discontinuation rates were assessed using Kaplan-Meier estimates
in adjusted models for cofounders using Cox proportional hazards regression modeling (Figs
1–4). At 36 months, drug retention rates due to lack of effectiveness (Fig 1) were as follows:
ABT (81.6%), TCZ (78.0%), GLM (76.5%), IFX (68.0%), ADA (67.3%), CZP (60.9%), and ETN
(55.4%) (Cox P<0.001). Drug retention rates due to toxic adverse events (Fig 2) were as fol-
lows: ABT (95.4%), CZP (92.9%), ETN (89.5%), ADA (86.3%), TCZ (86.3%), GLM (85.0%),
and IFX (79.3%) (Cox P = 0.043).
Fig 1. Drug survival rates due to lack of effectiveness in adjusted cases. Adjusted confounders were baseline age,
sex, disease duration, concomitant PSL and MTX, starting date and switched number of bDMARDs. ABT = abatacept,
ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab,
TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0216624.g001
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Drug retention rates due to remission (Fig 3) were as follows: CZP (100.0%), GLM (97.7%),
ADA (97.5%), ABT (96.8%), IFX (94.8%), ETN (94.4%), and TCZ (94.2%) (Cox P = 0.58).
Total drug retention rates (excluding non-toxic reasons and remission) were analyzed using
Kaplan-Meier estimates in adjusted model using Cox proportional hazards regression modeling
(Fig 4). At 36 months, drug retention rates were as follows: ABT (78.1%), TCZ (66.8%), GLM
(64.8%), ADA (57.6%), CZP (55.6%), IFX (52.5%), and ETN (50.0%), (Cox P<0.001).
Hazard ratios (HRs) and 95% confidence intervals (CI) for discontinuation due to each spe-
cific cause were calculated using multivariate Cox proportional hazards modeling, adjusted for
age, sex, disease duration, concomitant PSL and MTX, starting date and switched number of
bDMARDs (Table 2). HRs for total discontinuation (excluding non-toxic reasons and remis-
sion) were significantly higher with ADA (HR = 1.90, P = 0.0019), CZP (HR = 2.17,
P = 0.0025), ETN (HR = 2.36, P<0.001), and IFX (HR = 1.90, P = 0.0021) compared with
ABT, and differences were significant between the seven bDMARDs (P<0.001). In terms of
HRs for discontinuation due to lack of effectiveness, CZP (HR = 2.17, P = 0.0056) and ETN
Fig 2. Drug survival rates due to toxic adverse events in adjusted cases. Adjusted confounders were baseline age,
sex, disease duration, concomitant PSL and MTX, starting date and switched number of bDMARDs. ABT = abatacept,
ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab,
TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0216624.g002
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(HR = 2.22, P<0.001) showed significantly higher rates compared with ABT. Differences were
significant between the seven bDMARDs (P<0.001).
In terms of HRs for discontinuation due to all toxic adverse events, ADA (HR = 3.16,
P = 0.0076), ETN (HR = 2.50, P = 0.0020), GLM (HR = 3.58, P = 0.0014), IFX (HR = 3.62,
P = 0.0023), and TCZ (HR = 3.04, P = 0.0032) showed a significantly higher rate compared
with ABT, and the difference was significant between the seven bDMARDs (P = 0.043).
On the other hand, no significant differences were observed in HRs for discontinuation due
to non-toxic reasons (P = 0.62) or remission (P = 0.58).
Discussion
This retrospective study was designed to evaluated the retention rates and reasons for discon-
tinuation for seven bDMARDs in a real-world setting of elderly (65 years of age or more)
patients with RA.
Fig 3. Drug survival rates due to remission in adjusted cases. Adjusted confounders were baseline age, sex, disease
duration, concomitant PSL and MTX, starting date and switched number of bDMARDs. ABT = abatacept,
ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab,
TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs.
https://doi.org/10.1371/journal.pone.0216624.g003
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As for the effectiveness of bDMARDs in elderly patients, ABT was well tolerated and simi-
larly efficacious in both of the non-elderly (<65 years) and elderly (�65 years) RA patients
[25]. In addition, from the post hoc analysis of post-marketing surveillance in Japan, GLM
showed comparable improvement of disease activity between younger (<75 years) and elderly
(�75 years) patients [26].
In terms of toxic adverse events, ABT showed a lower risk of hospitalized infection com-
pared with TNFi [27], and also all other bDMARDs [28]. Another large cohort study demon-
strated that ABT was associated with a 20% reduced risk of cardio-vascular events versus TNFi
[29], and another recent report suggested the effectiveness of ABT in RA-associated interstitial
lung disease [30], which may lead to lower toxic adverse events of ABT in the present study.
On the other hand, recent report showed that the risk for toxic adverse events such as lupus-
like events and vasculitis-like events tended to be lowest with CZP compared with other TNFi
Fig 4. Overall drug survival rates (excluding non-toxic reasons and remission) in adjusted cases. Adjusted
confounders were baseline age, sex, disease duration, concomitant PSL and MTX, starting date and switched number
of bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept,
GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic
drugs.
https://doi.org/10.1371/journal.pone.0216624.g004
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[31]. In addition, the incidence of serious infections across bDMARDs in patients with RA
was not higher with CZP compared with other bDMARDs [32].
Finally, with respect to the total drug persistency, Jones et al. showed that treatment persis-
tence was longer on ABT or TCZ followed by TNFi [33], and we have also reported that both
ABT and TCZ showed higher retention rate compared with other TNFi in all ages [20]. Con-
cerning patients with TNFi failure, both ABT and TCZ showed similar substantial improve-
ment in clinical disease activity [34], and also good retention rates [35]. Concerning TNFi, a
recent report demonstrated that GLM showed higher persistency compared with other TNFi
when matched with propensity score in Japanese RA patients [36]. Taken together, ABT, TCZ,
and GLM may have some advantages in total drug persistency compared to other bDMARDs,
which was consistent with the present study. This phenomenon may be partially due to small
dose and ratio of concomitant MTX in this study, which may affect other TNFi effectiveness
more stronger than that of non-TNFi.
Other factors affecting bDMARDs retention and response have been reported. Higher age
[3], sex [5], concomitant PSL [3], high DAS28 or HAQ [3, 15, 37], absence or low dose of com-
bined MTX [3, 15], and the number of previously used bDMARDs [15] were the negative pre-
dictors in previous studies. With reference to these previous reports, we selected age, sex,
disease duration, concomitant PSL and MTX, starting date and switched number of
bDMARDs as the adjustment confounders in the present study.
Regarding the efficacy of low-dose MTX in Japanese populations compared with western
populations, intraerythrocyte MTX-polyglutamate (MTX-PG) concentrations, which have
been suggested to be a useful biomarker of efficacy, reached 94 nmol/L with 10.3 mg/week of
MTX in Japanese, compared to 65 nmol/L with 13.4 mg/week of MTX in the United States
[38]. As a result, a relatively low dose of MTX may exhibit positive effects on bDMARD reten-
tion in Japanese populations compared with western populations.
Some limitations to this study need to be considered. First, the judgment and reasons for
discontinuation (such as lack of effectiveness or remission) depended on the decisions of each
Table 2. Causes of treatment discontinuation at 36 months (Cox proportional hazards model, adjusted by baseline age, sex, disease duration, concomitant PSL and
MTX, starting date and switched number of bDMARDs).
































Lack of effectiveness 1 1.53 (0.96–
2.47)









All toxic adverse events 1 3.16 (1.36–
7.35)��









Non-toxic reasons 1 1.83 (0.82–
4.09)






















HR = hazard ratio; 95% CI = 95% confidence interval, ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab,
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physician, without standardized criteria. Second, the backgrounds of patients differed between
the agents, which may affect the results even adjusted by potent cofounders, and comorbidities
could not be evaluated. Third, the minor dose changes of bDMARDs, MTX, and PSL could
not be monitored. Fourth, the difference of intravenous and subcutaneous bDMARDs, and
the presence of other csDMARDs could not be determined. Fifth, CZP was licensed most
recently (2013) among seven bDMARDs in our country, which may lead to small number of
prescription that may affect the results.
However, the strength of this study is that this is the first study comparing treatment persis-
tency and discontinuation reasons of seven bDMARDs in elderly RA patients, and also the
treatment choice and discontinuation judgments were based on a real-world setting.
Conclusions
ABT showed lowest discontinuation rate by lack of effectiveness and by toxic adverse events,
which lead to highest overall retention rates (excluding non-toxic reasons and remission)
among seven bDMARDs in adjusted model of elderly RA patients.
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